Celldex Therapeutics has seen sharp swings in its share price over recent years, and fresh clinical news has pushed the story back into focus. The question now is whether the current market value of Celldex lines up with what its balance sheet and book value suggest the business is worth.
- Over the past 5 years the stock has fallen 41.7%, which makes the gap between recent price moves and the strength of its underlying assets a central issue for anyone thinking about valuation.
- Positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria may support expectations for future revenue and could affect how much weight investors put on Celldex's current book value versus its potential drug pipeline.
- The analysts covering Celldex Therapeutics have run their own numbers. See what analysts think Celldex Therapeutics's shares could be worth.
The issue now is whether Celldex's recent share price, after these swings and clinical updates, is justified by its book value relative to the industry average.
If you are weighing whether Celldex Therapeutics' recent swings line up with its book value, it can help to compare that question across 30 high quality undervalued stocks.
Has Celldex Therapeutics Run Too Far on Book Value?
P/B fits Celldex Therapeutics because it is a biotech that is still loss making and investors often look at the value of its net assets when earnings are not yet a key anchor.
The stock trades on a P/B of 3.5x, compared with a Biotechs industry average of about 2.1x and a peer group average near 3.3x. That points to Celldex carrying a premium to the sector overall and a smaller uplift versus closer peers, which suggests the market is already pricing in more than the current balance sheet alone might justify. Despite the strong Phase 3 barzolvolimab data lifting expectations for the pipeline, this richer multiple still frames Celldex as overvalued against the broader group on a pure book value lens. Explore the numbers behind Celldex Therapeutics's P/B valuation.
The Celldex Therapeutics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Celldex Therapeutics pick up where the P/B discussion leaves off by spelling out which paths for growth, margins and future earnings would need to play out for the valuation to look stretched or still conservative relative to today's share price. Each narrative ties its number to a specific view on how Celldex Therapeutics' prospects and risks might evolve, giving you a reference point you can revisit as fresh clinical or financial data arrives on the Community page.
One of the top community narratives on Celldex Therapeutics: 65% undervalued
"Barzolvolimab’s long duration of complete responses in chronic spontaneous urticaria and sustained control of angioedema well after drug and tryptase levels normalize…"
Discover why this Narrative puts Celldex Therapeutics at 65% undervalued.
Before focusing on Celldex Therapeutics' valuation, check what the risk checks are flagging
Price ratios and pipeline potential only tell part of the Celldex Therapeutics story, since recent research has also highlighted specific concerns that could change how you read the numbers. Take a closer look at 3 warning signs (1 major) before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com